Allogeneic CD19-targeted CAR-T therapy (BRL-301) for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results